| Name | Title | Contact Details |
|---|
Leading the translation of RNA-modifying protein (RMP) biology into promising new therapies for cancer.
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We`re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer. We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine `Editors`, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we`ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
Alamar Biosciences is a biotechnology company that has developed a next generation proteomic platform with ultra high sensitivity and multiplexing capability for plasma protein detection and liquid biopsies.
Advanced Vision Therapies is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MouldWorks is a Beulah, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.